<DOC>
	<DOCNO>NCT01183598</DOCNO>
	<brief_summary>This open-label , single center study provide RoActemra/Actemra ( tocilizumab ) maximum 4 patient Multicentric Castelman 's Disease demonstrate benefit RoActemra/Actemra study MRA004US ( Chugai Pharma USA ) without major toxicity significant adverse event . Patients receive effective maintenance dose disease progression significant toxicity occur .</brief_summary>
	<brief_title>A Study Provide RoActemra/Actemra ( Tocilzumab ) Patients With Multicentric Castleman 's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment</brief_title>
	<detailed_description />
	<mesh_term>Giant Lymph Node Hyperplasia</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Evidence improvement one clinical benefit criterion acceptable tolerability RoActemra/Actemra Protocol MRA001US , maintain clinical benefit MRA004US , completion MRA004US Life expectancy &gt; 12 week Zubrod performance status &lt; /= 3 Serious toxicity include anaphylactic reaction tocilizumab MRA004US trial Any treatment Multicentric Castleman 's Disease except corticosteroid within 2 week prior Day 1 Active infection require iv antibiotic &gt; 1 month resolve least 1 week prior Day 1 ; iv antibiotic prophylaxis infection implant venous access portal allow Active viral infection within 28 day prior Day 1 Treatment investigational agent RoActemra/Actemra within 30 day prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>